
-
Eledon Pharmaceuticals NasdaqCM:ELDN Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Location: 19800 MacArthur Boulevard, Irvine, CA, 92612, United States | Website: https://eledon.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
61.03M
Cash
124.9M
Avg Qtr Burn
-13.65M
Short % of Float
3.40%
Insider Ownership
1.40%
Institutional Own.
68.52%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tegoprubart (AT-1501) Details Type 1 diabetes, Islet Cell Transplantation | Phase 2 Data readout | |
Tegoprubart (AT-1501) Details Kidney transplantation | Phase 2 Data readout | |
Tegoprubart (AT-1501) Details Amyotrophic lateral sclerosis | Phase 2 Update | |
Tegoprubart (AT-1501) Details Kidney transplantation | Phase 1b Data readout | |
Tegoprubart (AT-1501) Details Autoimmune nephritis | Failed Discontinued | |
Tegoprubart (AT-1501) Details IgA nephropathy | Failed Discontinued |